Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Loading...
Community
/
Canada
/
Pharmaceuticals & Biotech
/
Aurora Cannabis
ACB
Aurora Cannabis
European Cannabis Regulations And Intense Competition Will Hamper Expansion
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 4 Analysts
Published
24 Aug 25
Updated
28 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
CA$6.00
23.0% overvalued
intrinsic discount
28 Aug
CA$7.38
1Y
-7.8%
7D
12.2%
Loading
1Y
-7.8%
7D
12.2%
Author's Valuation
CA$6.0
23.0% overvalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
CA$6.0
23.0% overvalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-3b
412m
2015
2017
2019
2021
2023
2025
2027
2028
Revenue CA$411.6m
Earnings CA$5.0m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
5.99%
Pharma revenue growth rate
0.59%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
5.97%
Calculation
CA$4.96m
Earnings '28
x
87.84x
PE Ratio '28
=
CA$435.52m
Market Cap '28
CA$435.52m
Market Cap '28
/
61.46m
No. shares '28
=
CA$7.09
Share Price '28
CA$7.09
Share Price '28
Discounted to 2025 @ 5.97% p.a.
=
CA$5.95
Fair Value '25
